Stroke patients treated intravenously with loberamisal, a novel neuroprotective medication, daily for 10 days and starting ...

AIM: The “2026 Guideline for the Early Management of Patients With AIS” replaces the “2018 Guidelines for the Early Management of Patients With AIS” and the 2019 update to reflect recent advances in ...

In A Nutshell A wearable “intelligent throat” device allows stroke patients with dysarthria to communicate by silently mouthing words—no sound required The smart choker achieved 96% word accuracy and ...

Manual review of electronic health records (EHRs) to screen for contraindications to thrombolysis during stroke evaluation is ...

The PSD-95 inhibitor also had a favorable safety profile in phase III trial ...

Late-Breaking Science Abstract LB 032 - In a phase III clinical trial in China, stroke patients treated intravenously with loberamisal, a novel neuroprotective medication, daily for 10 days starting ...

This “long overdue” update expands the pools of patients eligible for thrombolysis and thrombectomy, and tackles pediatric ...

Results from the CHOICE-2 trial show a 15% absolute increase in excellent functional outcomes with intra-arterial alteplase ...

Clinical trial results indicate a protein, rFVIIa, may benefit certain stroke patients when administered quickly, with a focus on acute intracerebral hemorrhage treatments.

The rationale behind the treatment is that, because genetic FXI deficiency has been linked with reduced risk of ischemic ...

As stroke systems of care evolve, clinicians are increasingly torn between the known safety of traditional, aggressive ...

ORLANDO, Fla. — According to the CDC, every year, nearly 800,000 people have a stroke in the United States. During May’s Stroke Awareness Month, doctors at Orlando Health want to lessen those numbers ...